Clinical trials
Cytomegalovirus Infections clinical trials
Below are recruiting cytomegalovirus infections clinical trials, each written for real people, not researchers. We’re tracking 45 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06554197Recruiting
CMV and EBV immune testing in half-matched stem cell transplant
This trial is for patients with blood disorders who are getting a half-matched stem cell transplant (from a family donor). It tests a new way to measure your immune system's response to two common viruses (CMV and EBV) after transplant, which may help doctors prevent or treat infections better.
Suzhou, JiangsuAges 16–60 - NCT06027879Enrolling by invitationPhase 1/Phase 2
Anti-viral T-cell therapy for stubborn viral infections after transplant
This trial tests a treatment using specially grown T-cells (a type of immune cell) to fight certain viruses that won't go away with standard medicines. It is for people who have had a stem cell or organ transplant, or who have a weak immune system, and who are struggling with adenovirus, CMV, or EBV infections.
Pittsburgh, PennsylvaniaAges 1 month–65 years - NCT06555432Recruiting
Study of maribavir for CMV infection after transplant
This study tests a medication called LIVTENCITY (maribavir) for adults in South Korea who have a CMV infection after a transplant. It is for people whose infection has not improved or has become resistant to other antiviral medicines.
SeoulAges 19 years+ - NCT05664126RecruitingPhase 2
Donor immune-cell treatment for stubborn CMV or adenovirus after transplant
This trial tests virus-fighting immune cells (T-cells) made from a donor to treat stubborn CMV or adenovirus infections after a blood and bone marrow transplant. It may help clear the virus when standard antiviral medicines are not working.
Memphis, TennesseeAges Up to 18 years - NCT05446571RecruitingPhase 3
Letermovir in pregnancy versus valaciclovir for fetal CMV
This trial tests whether letermovir can treat a baby’s early (first-trimester) congenital CMV infection in pregnancy, compared with the standard drug valaciclovir. The goal is to reduce serious effects from CMV while monitoring safety and pregnancy outcomes.
ParisAges 18 years+ - NCT06522880Recruiting
CMV transmission and immune tracking study
This study looks at how cytomegalovirus (CMV) spreads among children and staff at daycare centers. It uses a simple saliva test to check for the virus, which can help researchers better understand how to keep people healthy.
Worcester, MassachusettsAges 1 day–3 years - NCT07009548Enrolling by invitationPhase 4
CytoGam for CMV in solid organ transplant recipients
This trial tests whether adding CytoGam (an antibody treatment) to standard antiviral therapy can better treat CMV (a common virus) in people who have received a solid organ transplant. It may help those with high virus levels or a new infection after transplant.
Pittsburgh, PennsylvaniaAges 18–75 - NCT07688759Recruiting
Immune response measurement for first CMV after transplant
This trial is for adults who have had a stem cell transplant and now have their first CMV infection. It tests a way to measure your immune response to CMV, which may help doctors decide the best treatment for you.
Suzhou, JiangsuAges 18 years+ - NCT06916195Recruiting
CMV virus reactivation in kids after stem cell transplant
This study looks at how often a common virus (CMV) becomes active again in children after a stem cell transplant from a donor. It will help doctors understand more about this risk and how to manage it.
GenovaAges birth–18 years - NCT07013370Recruiting
Preventing CMV in Children After Stem Cell Transplant
This trial tests whether a special antibody treatment (CMV-specific immunoglobulin) can prevent CMV infections in children who have had a stem cell transplant from a donor. It may help protect your child’s immune system during recovery.
TriesteAges 1 month–18 years - NCT05708508RecruitingPhase 3
Immune-guided vs universal medicine to prevent CMV after kidney transplant
This study compares two strategies to prevent a viral infection called CMV after kidney transplant. It tests whether an “immune-guided” approach (using your immune test results) can prevent CMV as well as or better than giving preventive antiviral medicine to everyone.
RouenAges 18–75 - NCT04056533RecruitingPhase 2
Preventing CMV after a haploidentical stem cell transplant
This Phase 2 study tests a preventive “cell therapy” made from a donor’s immune cells to lower the risk of CMV infection after a haploidentical stem cell transplant. If you’re at risk for CMV, this may help protect you during the early post-transplant period.
SantanderAges 18–80 - NCT07235683RecruitingPhase 4
Stronger CMV treatment for lung transplant recipients
This trial tests adding a drug called letermovir to standard antiviral therapy for lung transplant patients with CMV infection. The goal is to see if the combination helps clear the virus faster and more effectively.
Toronto, OntarioAges 18 years+ - NCT04439916Recruiting
Preventing CMV after lung transplant in special donor/recipient pairs
This study looks at how to prevent and monitor a virus called CMV after a lung transplant. It is for adults who are not carrying CMV themselves, but who receive lungs from donors who are CMV-positive, and it may help tailor safer follow-up care after transplant.
Edmonton, AlbertaAges 18 years+ - NCT05711667RecruitingPhase 3
Letermovir to prevent CMV after stem cell transplant in kids
This trial tests whether the medicine letermovir can prevent a common virus (CMV) from coming back after an allogeneic stem cell transplant in children. It may help lower the risk of CMV infection during the vulnerable period right after transplant.
Birmingham, AlabamaAges 2–18 - NCT06058858Recruiting
CMV reactivation after CAR-T cell therapy for leukemia or lymphoma
This study looks at how often a common virus called CMV reactivates—meaning it becomes active again—in patients who receive CAR-T cell treatment for leukemia or lymphoma. It aims to understand the risks and help doctors better manage care.
ParisAges 1–100 - NCT06066957RecruitingPhase 2
Oral letermovir to prevent CMV after heart or lung transplant
This trial tests if an oral medication called letermovir can prevent CMV infection in heart or lung transplant recipients who are at risk for CMV. It may offer a convenient option to protect against this virus after transplant.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06812598Recruiting
Extended letermovir to prevent CMV after stem cell transplant
This trial tests whether taking letermovir for a longer time can prevent CMV (a common virus) from reactivating in adults with certain risk factors after a donor stem cell transplant. If you're preparing for your first transplant and have a high-risk donor or conditioning, this study may be an option.
Suzhou, JiangsuAges 18 years+ - NCT05319353RecruitingPhase 3
Maribavir for kids with CMV after transplant
This Phase 3 trial tests maribavir (an anti-CMV medicine) in children and teens who get CMV infection after a stem cell or solid organ transplant. It aims to see whether the drug is safe and well-tolerated, and whether it can reduce the virus in the body.
Wilmington, DelawareAges Up to 17 years - NCT03354728RecruitingPhase 1/Phase 2
Vaccine trial for children with CMV after stem cell transplant
This trial studies a vaccine designed to help the body fight cytomegalovirus (CMV) in children who test positive for CMV and are about to receive a donor stem cell transplant. If it works, it may reduce CMV-related illness during recovery after transplant.
Duarte, CaliforniaAges 1–21 - NCT07358910Recruiting
Tracking infectious diseases in communities
This study looks at how infections spread in villages in Cambodia. If you live in a participating village, you might help us understand and prevent disease outbreaks.
Phnom Penh, Phnom PenhAges 2–75
Hear when a new Cytomegalovirus Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cytomegalovirus infections?
- Yes. Clin2 currently lists 45 recruiting cytomegalovirus infections studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cytomegalovirus infections trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cytomegalovirus infections trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.